Acesis Holdings Corporation (ACSB)

Acesis Holdings will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$4.00 - $6.00
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 80.61M
Revenue (ttm) n/a
Net Income (ttm) -1.55M
Shares Out 16.12M
EPS (ttm) -0.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ACSB

Acesis Holdings Corporation together with its wholly-owned subsidiaries, is an emerging, pre-phase 1 (first-in-man “FIM”) clinical, biotechnology company focused on men’s health. Since the incorporation of ABI in the State of Colorado on March 11, 2015, we have been developing novel treatments for low testosterone levels in males (“Low–T”). The Company’s point of differentiation, compared to its competitors, is that its drug pipeline (peptides) is not a steroid or a hormone, but is intended to induce the body (specifically, the testes, which is... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ACSB
Full Company Profile

Financial Performance

Financial Statements


Acesis Holdings IPO Registration Document (S-1)

Acesis Holdings has filed to go public with an IPO on the NASDAQ.

10 months ago - SEC